Literature DB >> 17348451

Significance of lymphangiogenesis as assessed by immunohistochemistry for podoplanin in patients with esophageal carcinoma.

Yoshifumi Nakayama1, Kentaro Matsumoto, Masaru Nagato, Yuzuru Inoue, Takefumi Katsuki, Noritaka Minagawa, Kazunori Shibao, Yosuke Tsurudome, Keiji Hirata, Aiichiro Higure, Tatsuhiko Sako, Naoki Nagata.   

Abstract

BACKGROUND: Although lymph node involvement is an important prognostic factor for survival in patients with esophageal carcinoma, little is known about lymphangiogenesis in esophageal carcinoma. Podoplanin, a mutin-type transmembrane glycoprotein, specifically recognizes the lymphatic endothelium and is used as a lymphatic-specific marker. Anti-human podoplanin antibody was therefore used to quantify and evaluate the lymphangiogenesis in esophageal carcinoma. PATIENTS AND METHODS: Lymphatic endothelial cells were detected by immunohistochemistry using mouse monoclonal anti-human podoplanin antibody. The relationship between lymphatic microvessel density (LMVD) and lymphatic vessel invasion (LVI), clinicopathological factors and the prognosis in 29 patients with esophageal carcinoma was investigated.
RESULTS: LMVD was significantly higher in esophageal carcinoma patients who had any of the following characteristics: T3-T4 (p=0.0370), tumors more advanced than stage III (TNM staging) (p=0.0351), lymphatic invasion (p=0.0095) and LVI (+) (p=0.0016). LVI significantly correlated with lymph node metastasis (p=0.0003), TNM staging (p=0.0182) and LMVD (p=0.0388). The survival rate of patients with a low LMVD tended to be higher than that of patients with a high LMVD (5-year survival rate, 62.5% vs. 29.4%, p=0.0832).
CONCLUSION: The evaluation of lymphangiogenesis using podoplanin immunohistochemistry may be useful in predicting lymph node metastasis and the prognosis in patients with esophageal carcinoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17348451

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  Expression of podoplanin in the invasion front of oral squamous cell carcinoma is not prognostic for survival.

Authors:  Juan Carlos de Vicente; Tania Rodríguez Santamarta; Juan Pablo Rodrigo; Juana María García-Pedrero; Eva Allonca; Verónica Blanco-Lorenzo
Journal:  Virchows Arch       Date:  2015-03-01       Impact factor: 4.064

2.  Prognostic value of vascular endothelial growth factor-C and podoplanin mRNA expression in esophageal cancer.

Authors:  Agnieszka Juchniewicz; Wiesława Niklińska; Oksana Kowalczuk; Wojciech Laudański; Anetta Sulewska; Piotr Dziegielewski; Robert Milewski; Wojciech Naumnik; Mirosław Kozłowski; Jacek Nikliński
Journal:  Oncol Lett       Date:  2015-10-22       Impact factor: 2.967

3.  Peritumoral retraction clefting correlates with advanced stage squamous cell carcinoma of the esophagus.

Authors:  Tatjana Bujas; Ivana Pavić; Tanja Lenicek; August Mijić; Bozo Kruslin; Davor Tomas
Journal:  Pathol Oncol Res       Date:  2008-04-16       Impact factor: 3.201

4.  Lymphangiogenesis and angiogenesis in abdominal aortic aneurysm.

Authors:  Masaki Sano; Takeshi Sasaki; Satoshi Hirakawa; Junichi Sakabe; Mikako Ogawa; Satoshi Baba; Nobuhiro Zaima; Hiroki Tanaka; Kazunori Inuzuka; Naoto Yamamoto; Mitsutoshi Setou; Kohji Sato; Hiroyuki Konno; Naoki Unno
Journal:  PLoS One       Date:  2014-03-20       Impact factor: 3.240

5.  Identification of a novel platelet antagonist that binds to CLEC-2 and suppresses podoplanin-induced platelet aggregation and cancer metastasis.

Authors:  Yao-Wen Chang; Pei-Wen Hsieh; Yu-Tsui Chang; Meng-Hong Lu; Tur-Fu Huang; Kowit-Yu Chong; Hsiang-Ruei Liao; Ju-Chien Cheng; Ching-Ping Tseng
Journal:  Oncotarget       Date:  2015-12-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.